Trial Profile
A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 07 Feb 2023 Status changed from planning to withdrawn prior to enrolment.
- 09 Sep 2019 According to a CytoDyn media release, FDA has completed safety review of application for this study and allowed to proceed with the study.
- 14 Aug 2019 New trial record